Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

Firas Badin
John Hayslip
University of Kentucky, Markey Cancer Center, Lexington, KY, USA

Abstract: Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent clinical trials investigating the addition of rituximab to standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma. This report focuses upon treatment efficacy, quality of life, and safety of rituximab or rituximab-containing regimens. More uniquely, we review economic aspects of lymphoma treatments, including the cost of standard chemotherapy regimens with or without rituximab, cost effectiveness of rituximab in both induction and maintenance treatment, and lymphoma’s impacts on patient’s productivity and their caregivers. We conclude that adding rituximab to standard chemotherapy treatment for patients with B-cell non-Hodgkin lymphoma is safe and cost-effective in numerous settings during both induction and maintenance therapies. Despite extensive review of the literature, many important questions have yet to be answered in the rituximab era and these represent important directions for future study.

Keywords: rituximab, lymphoma, cost effectiveness, transplant, safety

Introduction
Rituximab, an anti-CD20 monoclonal chimeric antibody, has significantly improved the prognosis of patients with B-cell non-Hodgkin lymphoma (NHL) and changed the economics of care delivery for these patients. Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of B-cell NHL accounting for approximately 25% of NHL cases.\(^1\)\(^2\) In 2005 the incidence rate of DLBCL in the United States was approximately 5 cases per 100,000 persons. Incidence varies by ethnicity with Caucasian Americans having the highest rates. Incidence increases with age; the median age at presentation is 64 years, and like most NHL there is a male predominance (male: female ratio 1.2:1).\(^3\) Follicular lymphoma (FL) is the second most common lymphoma in the western world accounting for more than 70% of indolent lymphomas and 22% of all NHL.\(^3\) It has 3 grades, grade I and II are indolent lymphomas while grade III is considered by many experts to be an aggressive lymphoma. It typically occurs in middle-aged or elderly adults with the median age at presentation of 60 years and a slight female predominance (male to female ratio 1:1.4).\(^3\)

Rituximab
Rituximab was the first widely adopted monoclonal antibody approved for cancer treatment. Rituximab is a monoclonal antibody directed against the CD20 antigen on B-lymphocytes. CD20 functions as a calcium channel important in B-cell survival.
Rituximab’s mechanism of action results from a combination of immune-mediated effects and possibly direct induction of apoptosis from binding to CD20. When rituximab binds to CD20 at the cell surface rituximab activates complement-dependent cytotoxicity and human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity. As has been previously reviewed, the predominant mechanism of rituximab’s anti-lymphoma activity is thought to be antibody-dependent cell-mediated cytotoxicity, with a lesser role for complement fixation. Although rituximab has multiple clinical uses, including autoimmune and hematologic disorders, this review focuses upon rituximab’s use in B-cell NHL.

**DLBCL treatment**

The addition of rituximab concurrently with cytotoxic chemotherapy has improved the cure rates for patients with DLBCL (Table 1). Prior to the introduction of rituximab, SWOG-8516 (South Western Oncology Group) a randomized phase III trial of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) vs m-BACOD (low-dose methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) established that CHOP remained the standard chemotherapy for patients with advanced stage NHL demonstrating intermediate or higher grade histologic features. Although other regimens induced greater toxicities, no regimen showed an improvement in time to treatment failure or overall survival compared to the standard CHOP. The addition of rituximab to CHOP resulted in an approximately 10% absolute increase in survival beginning at one year from initiation of therapy in patients of all ages with minimal clinically relevant increases in toxicity. In the MabThera International Trial (MinT), 824 patients younger than 60 years with DLBCL (28% stage III/IV and 48% with bulky disease) were randomly assigned to treatment with 6 cycles of CHOP-like chemotherapy with or without rituximab. Bulky and extra-nodal sites received additional radiotherapy. After a median follow-up of 34 months, patients assigned to Rituximab-CHOP (R-CHOP) had significantly higher rates of 3-year event-free (79% vs 59%; \( P < 0.001 \)) and overall (93% vs 84%; \( P < 0.0001 \)) survival. In 3 randomized prospective studies consisting of approximately 2000 older patients (>65 years of age) with advanced DLBCL, therapy with R-CHOP resulted in significantly higher overall survival at 3 (approximately 70% vs 57% for CHOP alone), 5 (58% vs 45%), and 7 years.

Following these reports that the addition of rituximab to CHOP improved response rates and overall survival, further studies were conducted to investigate the impact of maintenance rituximab after initial chemotherapy. Patients who received CHOP chemotherapy for induction treatment have an initially improved survival when administered maintenance rituximab following CHOP chemotherapy compared to patients who received CHOP chemotherapy only. However, survival benefit disappeared with longer follow-up suggesting that unlike induction combination chemotherapy with rituximab, rituximab maintenance may delay clinically evident progression but does not increase the cure rate. Additionally, maintenance therapy with rituximab provided no significant benefit in those who received initial therapy with R-CHOP for DLBCL.

Although the addition of rituximab to CHOP has improved the cure rates for patients with DLBCL,
a significant portion of patients still have recurrence and require additional therapies. Rituximab may play an important role in addition to standard chemotherapies in this setting as well. Thirty-six patients with relapsed or refractory DLBCL were treated with rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE). The complete response rate was 53%, significantly better than the historical control rate of 27% achieved for DLBCL treated with ICE alone (P = 0.01). Progression-free survival rates of patients who underwent transplantation after R-ICE trended toward improvement compared to historical controls who underwent transplantation after ICE (54% vs 43% at 2 years) but weren’t statistically significant in this analysis (P = 0.25). The ICE and R-ICE regimens have been very effective cyto reduction and stem cell mobilization regimens, and reasonable options for patients eligible for subsequent hematopoietic stem cell transplant (HSCT). Hematopoietic stem cell transplantation (HSCT) is a clinically necessary treatment for many patients with DLBCL and significantly impacts the economics of these patients’ care. In the United States, autologous HSCT is considered standardof-care for many patients who achieve a second remission from DLBCL following a first recurrence. HSCT during the first remission is associated with significant morbidity and survival is similar in patients administered chemotherapy with or without HSCT. An intergroup trial (S9704) enrolled patients with high intermediate and high risk international prognostic index (IPI) scores according to age-adjusted index and randomized treatment to 6 cycles of R-CHOP followed by autologous HSCT vs 8 cycles of R-CHOP alone. We await results of this United States intergroup trial before recommending HSCT for this subgroup of patients. Including rituximab with HSCT may improve the clinical results achieved with HSCT chemotherapy alone. A Phase III randomized trial (CORAL) comparing two rituximab-based regimens both followed by HSCT and maintenance rituximab or not in relapsed or refractory DLBCL found that rates of 2-year event-free survival were significantly reduced in a subset of patients with prior exposure to rituximab when compared with patients who were rituximab-naïve. In one modest-sized study, rituximab was given to 35 patients with recurrent or refractory aggressive NHL (25 with DLBCL) following high-dose therapy and autologous HSCT. Rituximab was given for 4 weeks starting at day 42 post-HSCT in all patients, and again at 6 months post-HSCT in 31 patients. At a median follow-up of 30 months, the estimated 2-year event-free and overall survivals were 81% and 85%, respectively, for the 21 patients a

with relapsed or refractory DLBCL. Although delayed and severe neutropenia, including some patients with an absolute neutrophil count less than 500/mm³, as well as profound B-cell inhibition were observed, the treatment program was well-tolerated. In a second trial, high-dose rituximab, 1000 mg/m² rather than standard-dose 375 mg/m², was administered during stem cell mobilization, BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy, and on days 1 and 8 after HSCT in 67 patients. At a median follow-up of 20 months, estimated 2-year disease-free and overall survival (OS) were 67% and 80%, respectively (P = 0.002), significantly better than those of a historical control group receiving the same preparative regimen without rituximab 43% and 53%, respectively (P = 0.004).

FL treatment

Unlike DLBCL, no consensus exists for a standard-of-care initial treatment for patients with newly diagnosed FL. Indeed, the decision to begin treatment as opposed to continued observation is often a subjective decision. In the United States, significant regional variations exist in the care of patients with FL. For example, initial observation without treatment was recommended for 29% of patients in the northeast but only 13.3% of patients in the southeast. Cyclophosphamide, doxorubicin, and fludarabine based regimens may all be considered for first and subsequent treatments (Table 2).

The most commonly prescribed initial treatment for FL is R-CHOP, the same regimen that is considered standard-of-care for DLBCL. The initial trial of R-CHOP for patients with de novo and recurrent FL reported a 95% response rate and 55% complete response rate. Subsequently, a randomized trial of CHOP vs R-CHOP for initial treatment of patients with FL reported a 90% response rate and 17% complete response rate for CHOP vs 96% and 20% respectively for R-CHOP (P = 0.011). For patients who do not receive CHOP for initial therapy, CHOP is often considered for second line therapy. As a second-line treatment, R-CHOP therapy has a significantly higher complete response rate than CHOP therapy alone, 30% vs 16% (P < 0.0001), which translated into a significantly prolonged median progression-free survival (PFS) from first randomization, 33.1 vs 20.2 months (P = 0.0003).

Another common FL treatment regimen, cyclophosphamide, vincristine, and prednisone (CVP) is significantly improved with the addition of rituximab. Adding rituximab to CVP (R-CVP) in previously untreated patients with stage III/IV FL improves complete response rates from...
57% to 81% and improves overall survival after 53 months median follow up from 77% to 83% without increasing serious adverse events (P < 0.0001).

Regimens containing fludarabine, a nucleoside analogue, have shown high response rates and are another considerable regimen for initial and subsequent therapy for patients with FL. Patients receiving R-FCM (rituximab, fludarabine, cyclophosphamide, mitoxantrone) as induction therapy will achieve significantly higher complete response (CR) and overall response rates (ORR) than those who receive induction with FCM alone.\(^2\) In a trial that combined patients with relapsed FL and mantle lymphoma and randomized patients to receive FCM with or without rituximab, the R-FCM arm was significantly superior in ORR, PFS and OS. In the FL subgroup, the patients receiving the rituximab-containing induction arm had a 94% ORR vs 70% in FCM alone arm (P = 0.011); PFS was also significantly longer in the R-FCM arm (P = 0.0139).

More recently, bendamustine and rituximab (BR) combinations have been studied in patients requiring initial treatment of FL and in patients with relapsed disease. In the frontline setting, BR has a similar overall and complete response rate 94% and 41% compared to R-CHOP 93% and 33%.\(^28\) The R-CHOP arm also had more hematologic and infectious toxicities than the BR arm.\(^28\) For patients with relapsed FL, BR has reported a 92% response rate with 41% complete response in a study of 67 patients.\(^29\) Increasingly, BR is reasonable treatment option for initial or subsequent treatment for patients with FL.

Radioimmunotherapy, linkage of monoclonal antibody to radioisotope for intravenous administration, is another treatment option for patients with FL. In patients with advanced stage FL receiving \(^{131}\)I-tositumomab as initial therapy, 95% responded and 75% had a complete response.\(^30\) Radioimmunotherapy has also been investigated as a consolidation therapy after cytotoxic chemotherapy. An international, randomized, phase III trial evaluated the efficacy and safety of consolidation with \(^{90}\)Y-ibritumomab tiuxetan in patients with advanced-stage FL in first remission. Consolidation with \(^{90}\)Y-ibritumomab tiuxetan is highly effective with no unexpected toxicities, prolonging PFS by 2 years and resulting in high partial response (PR) conversion to CR rates with multiple first-line induction combinations.\(^31\)

Maintenance treatments with rituximab after patients are in remission from FL are effective at delaying time until recurrence in some instances for patients with FL. Two phase II trials of rituximab maintenance after rituximab monotherapy induction suggested that rituximab as a first-line treatment with scheduled maintenance at 6-month intervals produces high overall and complete response rates and a longer PFS, 34 months, than has been reported with a typical 4-week treatment alone.\(^32,33\) The Phase III Swiss Group for Clinical Cancer Research (SAKK) 35/98 trial enrolled both newly diagnosed and previously treated

**Table 2 Treatment of follicular lymphoma**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Treatment</th>
<th>Results</th>
<th>Schema</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hiddemann(^24)</td>
<td>CHOP</td>
<td>RR: 90% CR: 17%</td>
<td>1st line</td>
<td>P = 0.011</td>
</tr>
<tr>
<td>van Oers(^25)</td>
<td>CHOP</td>
<td>ORR: 72% CR: 16%</td>
<td>2nd line</td>
<td>P &lt; 0.001</td>
</tr>
<tr>
<td>Marcus(^26)</td>
<td>CVP</td>
<td>ORR: 70% CR: 23%</td>
<td>1st line</td>
<td>CR &lt; 0.0001</td>
</tr>
<tr>
<td>Forstpointner(^27)</td>
<td>FCM</td>
<td>ORR: 93% CR: 33%</td>
<td>1st line</td>
<td>Not reported</td>
</tr>
<tr>
<td>Robinson(^29)</td>
<td>BR</td>
<td>ORR: 92% CR: 41%</td>
<td>2nd line</td>
<td>CI 95%</td>
</tr>
</tbody>
</table>

52% of the patients had follicular lymphoma, 20% had mantle cell lymphoma and 28% had other lymphoma.

patients had indolent non-Hodgkin lymphoma and mantle cell lymphoma.

Abbreviations: CI, confidence interval; RM, rituximab maintenance; OBS, observation; BR, bendamustine with rituximab; mo, month; RR, response rate; CR, complete response; ORR, overall response rate; PFS, progression-free survival; OS, overall survival.
patients with FL. Overall, 151 patients (51 of whom were previously untreated) achieved CR, PR, or stable disease after rituximab monotherapy induction (four once weekly doses) and were subsequently randomized to either no further treatment or rituximab maintenance therapy consisting of four single rituximab infusions administered at 2-month intervals. In the initial publication, with a median follow-up of 35 months, median event-free survival among all patients receiving maintenance therapy was significantly longer than that achieved by patients receiving no further treatment, 23 vs 12 months (P = 0.024). With 8 years of follow-up, no long-term toxicities were attributable to maintenance rituximab and 20% of patients still remained in remission. Overall this study showed that rituximab maintenance after rituximab monotherapy induction significantly improves outcomes in FL in terms of both response duration and event free survival, without causing additional toxicity. Recently, a comprehensive review and meta-analysis concluded that maintenance therapy with rituximab, either as 4-weekly infusions every 6 months or as a single infusion every 2 to 3 months, should be added to standard therapy for patients with relapsed or refractory FL after successful induction therapy.

Rituximab maintenance after initial chemotherapy induction is significantly better than induction chemotherapy alone. A Phase III trial conducted by the Eastern Co-operative Oncology Group (ECOG 1496) studied 305 evaluable patients with newly diagnosed advanced stage indolent NHL. Most of these patients, 78%, had advanced stage FL. Those patients achieving a complete or partial response or stable disease following CVP induction chemotherapy were randomized to either rituximab maintenance therapy or standard observation. The rituximab maintenance was dosed weekly for 4 doses and repeated at 6-month intervals for up to 2 years. Analyses conducted in the FL subgroup revealed 3-year PFS after random assignment was 64% for the maintenance group vs 33% for the observation group (hazard ratio [HR] = 0.4; P < 0.001). Among patients with FL, OS at 3 years was 91% for the maintenance group vs 86% for the observation group (HR = 0.6; P = 0.08). This study provides strong evidence that rituximab maintenance has a significant survival benefit for patients with FL who receive induction chemotherapy without the inclusion of rituximab during induction.

Similar, but more compelling, conclusions have been drawn in the relapsed setting. In European Organization for the Research and Treatment of Cancer (EORTC) protocol 20891, patients were randomized to CHOP or R-CHOP induction therapy for a first recurrence of FL. After six cycles of induction chemotherapy; patients who achieved complete or partial responses underwent another randomization to rituximab maintenance or standard observation. Rituximab maintenance significantly prolonged the PFS from 14.9 months in the observation to 51.5 months (P < 0.0001); rituximab maintenance also improved OS at 3 years from 77% with observation alone to 85%. In a subgroup analysis of patients who received CHOP for induction, rituximab maintenance resulted in a median PFS from second randomization of 42.2 months vs 11.6 months in the observation arm (HR, 0.30; P < 0.001). For patients receiving R-CHOP induction, rituximab maintenance resulted in a median PFS from second randomization 51.8 months vs 23.0 months in the observation arm (HR, 0.54; P = 0.004). As a conclusion from this study; rituximab maintenance was still beneficial after R-CHOP induction but a survival benefit was clearer in patients who only received CHOP induction.

Maintenance rituximab after autologous HSCT is another interesting treatment consideration. The efficacy and safety of rituximab maintenance therapy administered once monthly after autologous HSCT were retrospectively analyzed in 27 patients with NHL treated at a single institution. Of these 27 patients, 12 had FL and were in CR at the time of transplantation. After a median follow-up period of 30 months, all 12 patients were still alive and, except for 1 patient who transformed from indolent to aggressive disease, there were no relapses. Another study incorporated in vivo purging with rituximab around the time of stem cell pheresis with maintenance rituximab after autologous HSCT. Twenty-three patients with relapsed FL were enrolled in this prospective single-arm study. Five-year OS and 5-year PFS are 78% (95% confidence interval [CI] 61% to 95%) and 59% (95% CI 38% to 80%), respectively. Time to progression with the rituximab-containing regimen was significantly improved compared with each patient’s previous treatment (P < 0.001). Durable molecular remissions, documented by quantitative polymerase chain reaction testing, occurred in 11 of 13 patients. Despite the prolonged hypogammaglobulinemia, no increase in major infections was observed.

Cost of lymphomas
The loss of life-years from DLBCL is hard to estimate and we found no previous reports in our review of the literature. A retrospective analysis of 374 patients with newly diagnosed stage II–IV aggressive NHL treated between 1993 and 2001 in The Netherlands with CHOP chemotherapy showed the mean first-line treatment costs (excluding G-CSF) were €10,047 ($10,254) for patients younger than 60 years.
of age and €12,232 ($12,484) for patients older than 60.\textsuperscript{40} Two-year follow-up costs averaged €14,039 ($14,328) and €9,026 ($9,211) for the two age groups, respectively. A large retrospective analysis of direct medical costs for the entire pathway of care for DLBCL was conducted between 1998 and 2004 in Canada.\textsuperscript{41} Patient samples were defined as those who received R-CHOP (n = 85) or CHOP (n = 86) as first-line treatment. CHOP cost was CAN$12,240 ($8,800) and the 1-year follow up cost was CAN$8,929 ($6,400) compared to R-CHOP cost of CAN$33,088 ($22,680) with 1-year follow up costs of CAN$3,215 ($2,311). In European healthcare systems between 2000 and 2003, the mean cumulative cost of CHOP was $3,358 and R-CHOP was $17,225.\textsuperscript{42} The post-treatment cancer surveillance cost for CHOP was $3,950 compared with $5,202 for R-CHOP.

Often thought of as one of the most costly treatments, HSCT adds significant expense to the care of patients who require this modality of care. For patients with refractory or relapsed NHL, the cost from induction chemotherapy until 3 months after discharge from inpatient care following the transplant was €15,000 ($15,300) from 1994 to 1998 in The Netherlands.\textsuperscript{43} Similarly, the cost for autologous HSCT for the Canadian system in 1993/1994 was CAN$22,089 ($16,029).\textsuperscript{44}

The loss of life-years is harder to estimate from FL because patients may undergo multiple series of treatments over a decade or more after diagnoses. Although the attempts to capture the costs of chemotherapy for FL have not always accounted for infusion related and follow up costs, in 2007 the cost of 8 cycles of CVP in the US was $500, 6 cycles R-CVP $24,500, and CHOP as salvage over 6 months costs $3,829.\textsuperscript{45} Further, autologous HSCT for treatment of FL in the US in 2007 was estimated to cost $75,352.\textsuperscript{45} Although this cost is much higher than reviewed for DLBCL, this difference is likely related to healthcare inflation and differences in cost between healthcare systems and not due to differences between the diseases. As with DLBCL, the cost to patients and families for lost productivity is likely significant, but has not been well measured.

Despite the extensive publications about NHL treatments, little is known about how treatment impacts on patients’ work and daily activities. A cross-sectional study of work productivity, activity impairment, and impacts on caregivers was conducted with 84 patients with NHL. Of the 71% of patients who worked before diagnosis; only 41% continue to work after treatment with 36% transitioning to retirement, sick leave (10%) and unemployment (4%).\textsuperscript{46} Active chemotherapy treatment was associated with significant activity impairment (OR 14.5; 95% CI 0.91 to 230.9; \( P = 0.059 \)). A significant proportion of patients required caregiver assistance (23%); with 33% of their working days being missed as a consequence of this care.\textsuperscript{46} Those caregivers suffered from physical, psychological, and financial disruptions. Another large cohort study reported that 13% of all survivors had stopped working for cancer-related reasons within 4 years of diagnosis. More than 50% of all survivors had stopped working after the first year with 75% of those who stopped working returning to work in the future when they are off treatment.\textsuperscript{47} Survivors of stage IV blood and lymph malignancies have one of the highest adjusted risk of disability or quitting work amongst all patients with cancer.\textsuperscript{47}

Given the high costs of these illnesses and their treatments; much work has gone into determining the most cost-effective approaches for care delivery (Table 3). A cost-effectiveness analysis of CHOP vs R-CHOP for initial treatment of patients with DLBCL has been presented from a European payer perspective.\textsuperscript{48} Chemotherapy cost was estimated from a phase III trial in France, Belgium, and Switzerland. The survival and cost-effectiveness was estimated from 4 years to 15 years. R-CHOP resulted in 20.6% relative increase in complete response rate, absolute increase from 63% to 76%, and a 31% decrease in risk of death at four years. Over 15 years mean, median OS was estimated to be 6.9 years for R-CHOP and 5.74 years for CHOP, a mean increase in OS of 1.16 years (or 1.07 quality adjusted life years [QALYs]). Total direct medical costs were €13,170 ($11,250) higher with R-CHOP, with an incremental cost-effectiveness ratio of €12,259 ($10,477) per QALY gained which looks favorable comparing to standard worldwide accepted ranges. Similarly, the incremental cost effectiveness of CHOP vs R-CHOP in DLBCL patients in Netherlands has been reported.\textsuperscript{49} A transition state model was developed to estimate the clinical course, costs and quality

\begin{table}[h]
\centering
\caption{Cost of diffuse large B-cell lymphoma treatment}
\begin{tabular}{|c|c|c|c|}
\hline
\textbf{Study} & \textbf{Treatment} & \textbf{Follow-up period} & \textbf{Cost} \\
 & & & \textbf{1st line} \textbf{Follow-up} \\
 & & & \textbf{cost} \textbf{cost} \\
\hline
Hornberger\textsuperscript{42} & CHOP & 5 years & $3,358 & $3,950 \\
\textbf{N = 399} & R-CHOP & & $17,225 & $5,202 \\
\hline
van Aghthoven\textsuperscript{43} & CHOP & 2 years & $10,254 & $9,211 \\
\textbf{N = 374} & R-CHOP & & $12,232 & $14,328 \\
\hline
Lee\textsuperscript{44} & CHOP & 1 year & $8,800 & $6,400 \\
\textbf{N = 171} & R-CHOP & & $22,680 & $23,111 \\
\hline
\end{tabular}
\end{table}
of life (QOL) differences between the two groups. The only costs included were direct medical costs. The time horizon of the model was 15 years. The incremental gain was 0.88 QALYs favoring the addition of rituximab to CHOP. The costs were €12,343 ($10,550) higher in the younger group of patients and €15,860 ($13,555) in the older patients. This resulted in an incremental cost-effectiveness ratio (ICER) of €13,983 ($11,950) for the younger and €17,933 ($15,327) for the older patients per QALY gained. An additional study compared the direct medical cost of CHOP and R-CHOP in young patients with favorable IPI risk DLBCL from the perspective of the Italian National Health Service. The model provided an estimate of mean survival and mean costs over a 3-year period. The QALYs gained with R-CHOP was greater than with CHOP. In the R-CHOP regimen, the additional costs of rituximab €10,086 ($14,780) were balanced by the lower additional therapy costs €10,803 ($15,830) leading to a lower overall mean treatment cost per patient with R-CHOP regimen than with the CHOP regimen €22,113 ($32,400) vs €22,831 ($33,460).

In FL, the cost effectiveness of adding rituximab to CVP has been reported and the mean overall survival is projected to be 1.51 years longer for patients receiving R-CVP than CVP. The cost per QALY gained is €28,565 and the ICER of R-CVP compared with CVP is projected to be acceptable under a range of sensitivity analyses in the United States. The cost-effectiveness of maintenance rituximab for US patients with FL in second remission has also been reported. Five years after R-CHOP and achieving a second remission, disease-free survival is expected to be 47% and 22%, and the OS rates are estimated to be 73% and 61% for extended adjuvant rituximab and observation, respectively. The discounted ICER for the addition of adjuvant rituximab is estimated to be €19,522 per QALYs gained. The authors concluded that maintenance rituximab offers a clinical benefit to patients who have a second remission from FL at a cost generally acceptable to the US healthcare system. Similarly, a cost-effectiveness analysis of maintenance rituximab during second remission for patients in Sweden was conducted and concluded to be a reasonable value for patients who achieve a complete response to induction chemotherapy.

**Patient focused outcomes**

The addition of rituximab to CHOP chemotherapy may not add significantly to the symptoms or toxicities of CHOP chemotherapy alone. QOL was evaluated during a prospective randomized trial of rituximab maintenance therapy in 91 NHL patients (38 with DLBCL and 16 with FL). QOL was assessed with the standardized questionnaires EORTC-QLQ-C30, EuroQol-5D, and EuroQol-5D (VAS). No differences in QOL were found between the groups that received rituximab maintenance or standard observation. We are not aware of any reports that have specifically ascertained patient satisfaction with receiving rituximab during treatment for DLBCL or adherence with treatment recommendations. Similarly, uptake of R-CHOP in place of CHOP seems nearly universal when health care systems are able to offer rituximab, although objective data to support this belief are lacking.

In FL, the addition of rituximab to CHOP did not clinically significantly increase the toxicity of induction therapy. In SAKK 35/98, maintenance rituximab was well tolerated. Of the 137 patients who were evaluable for toxicity, only 7% in both the maintenance and observation arms reported toxicities. In Eastern Cooperative Oncology Group (ECOG) protocol 1496, rituximab maintenance or observation after induction therapy with CVP, rituximab maintenance was well tolerated and did not lead to significantly higher rates of neutropenia, thrombocytopenia, or infection compared with observation alone. In EORTC 20891, rituximab maintenance vs observation after induction therapy with either CHOP or R-CHOP, rituximab maintenance treatment was associated with minimal toxicity. Only 6 out of 167 patients (4%) had to discontinue treatment because of toxicity. Four of the six patients were discontinued due to infections, and there was no treatment-related mortality. As in DLBCL, patient satisfaction, acceptability, physician uptake, and adherence have been widely reported and our literature review failed to return any relevant reports.

**Future directions**

Although there are many investigations of rituximab in NHL many questions still await an answer. Despite the fact that all studied maintenance schedules have been shown to be effective in FL; we are still unsure about the optimal dosing, schedule, and duration of this maintenance. Because all of the rituximab maintenance studies have been conducted over the last 7 years, there is no clear guidance yet about long term safety and efficacy. Questions remain about the risks of decreased immunoglobulin levels and infection rates, activating cutaneous squamous cell carcinoma, and selection for CD20 negative lymphoma relapses. Questions about the long-term safety require longer follow up. The impact of rituximab maintenance on patient’s QOL and productivity and caregiver burden should be studied further. Some researchers and advocates have suggested that receiving maintenance treatments may reduce QOL due to treatment
burden but others have advocated that maintenance may increase patient’s feeling of satisfaction as they participate in actively managing their disease. Further research is clearly indicated. Despite our careful review, we are not aware of data to assess patients’ acceptance or physicians’ uptake of rituximab. Although treatment with rituximab is clinically beneficial in several patient settings, future investigations may allow doctors and patients to optimize the treatment effect and refine approaches that improve patient-focused outcomes and limit economic burden.

Disclosures

The authors report no conflicts of interest.

References